Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of …

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for …

Do you trust this headline?

Based on recent headline ratings, 79% of this readership currently trusts the local media, which has an average score of 83% regionally and is currently trending negative.

79%

Media Trust Score